121443-79-6

Basic information

• Product Name: Benzenemethanamine, 2,6-dichloro-a-methyl-,(S)-
• Synonyms: Benzenemethanamine, 2,6-dichloro-a-methyl-,(S)-;Benzenemethanamine, 2,6-dichloro-α-methyl-, (S)- (9CI);6-dichloro-a-Methyl-;(S)-1-(2,6-DICHLOROPHENYL)ETHANAMINE-HCl;(S)-1-(2,6-Dichlorophenyl)ethanaMine hydrochloride;(S)-2,6-DICHLORO-ALPHA-METHYL-BENZENEMETHANAMINE;(1S)-1-(2,6-dichlorophenyl)ethanamine,hydrochloride;(S)- 2,6-dichloro-a-methyl-Benzenemethanamine
• CAS NO: 121443-79-6
• Molecular Formula: C₈H₉Cl₂N
• Molecular Weight: 190.07216
• Product Categories: API intermediates
• Mol File: 121443-79-6.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 248.142 °C at 760 mmHg
• Flash Point: 103.873 °C
• Appearance: /
• Density: 1.262 g/cm³
• PKA: 7.96±0.10(Predicted)
• CAS DataBase Reference: Benzenemethanamine, 2,6-dichloro-a-methyl-,(S)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanamine, 2,6-dichloro-a-methyl-,(S)-(121443-79-6)
• EPA Substance Registry System: Benzenemethanamine, 2,6-dichloro-a-methyl-,(S)-(121443-79-6)

Safety Data

• Hazardous Substances Data: 121443-79-6(Hazardous Substances Data)

Usage

General Description

Benzenemethanamine, 2,6-dichloro-a-methyl-,(S)- is a chemical compound that contains a benzene ring with a methanamine group and two chlorine atoms attached at the 2 and 6 positions. The (S)- designation indicates that the molecule is in its stereochemically pure form. Benzenemethanamine, 2,6-dichloro-a-methyl-,(S)- is used in various chemical and pharmaceutical applications, including as an intermediate in the synthesis of other organic compounds and as a chiral building block in the creation of pharmaceuticals and agrochemicals. Its specific properties and uses may vary depending on its intended application and the methods used to produce and modify it.

Upstream product

• 121443-78-5 (1S)-N-Trimethylsilyl-1-(2-chlorophenyl)ethylamine 
• 2627-86-3 (S)-1-phenyl-ethylamine 
• 68285-26-7 (S)-α-(o-chlorophenyl)ethylamine 
• 121443-77-4 N-<(S)-1-phenylethyl>(trimethylsilyl)amine 

Downstream Products

• 121443-83-2 (S)-N-<2-(3,4-Dimethoxyphenyl)ethyl>-1-(2,6-dichlorophenyl)ethylamine 
• 121443-88-7 (S)-N-<1-(2,6-Dichlorophenyl)ethyl>-N-<2-(3,4-dimethoxyphenyl)ethyl>acetamide 
• 121443-89-8 (S)-N-<1-(2,6-Dichlorophenyl)ethyl>-N-<2-(3,4-dimethoxyphenyl)ethyl>propanamide 
• 121443-90-1 (S)-N-<1-(2,6-Dichlorophenyl)ethyl>-N-<2-(3,4-dimethoxyphenyl)ethyl>-2-methylpropanamide 
• 121443-91-2 (S)-N-<1-(2,6-Dichlorophenyl)ethyl>-N-<2-(3,4-dimethoxyphenyl)ethyl>(3,4-dimethoxyphenyl)acetamide 
• 126017-65-0 (6R)-(+)-1-<(1S)-1-(2,6-Dichlorophenyl)ethyl>-6-(1-prop-2-enyl)-2-piperidinone 
• 126017-65-0 6-Allyl-1-[(S)-1-(2,6-dichloro-phenyl)-ethyl]-piperidin-2-one 
• 126035-20-9 1-<(1S)-1-(2,6-Dichlorophenyl)ethyl>-6-hydroxy-2-piperidinone 
• 126035-17-4 1-<(1S)-1-(2,6-Dichlorophenyl)ethyl>glutarimide 
• 126017-80-9 1-[(S)-1-(2,6-Dichloro-phenyl)-ethyl]-5-hydroxy-pyrrolidin-2-one 
• 126017-89-8 5-Allyl-1-[(S)-1-(2,6-dichloro-phenyl)-ethyl]-pyrrolidin-2-one 
• 121443-81-0 (S)-N-<1-(2,6-Dichlorophenyl)ethyl>-2-(3,4-dimethoxyphenyl)acetamide 
• 126017-63-8 4-[1-(2,6-Dichloro-phenyl)-ethylcarbamoyl]-butyric acid 

Relevant articles and documents

N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG

The invention provides molecular entities that bind with high affinity to PPARG (PPAR3), inhibit kinase-mediated, e.g., cdk5-mediated, phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes, insulin resistance, impaired glucose tolerance, pre-diabetes, hyperglycemia, hyperinsulinemia, obesity, or inflammation. In methods of treatment of these conditions using a compound of the invention, the compound can avoid producing side effects of significant weight gain, edema, impairment of bone growth or formation, or cardiac hypertrophy, or any combination thereof, in the patient receiving the compound. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.

Stereoselective Nucleophilic Additions to the Carbon-Nitrogen Double Bond. 2. Chiral Iminium Ions Derived from "Second Generation" Chiral Amines

"Second generation" chiral amines (1S)-(-)-1-(2-chlorophenyl)ethylamine (4) and (1S)-(-)-1-(2,6-dichlorophenyl)ethylamine (5) have been prepared from commercially available (S)-(-)-α-phenethylamine.These chiral reagents have been incorporated into chiral